EHS
EHS

FDA Approves Encorafenib and Binimetinib Combo for Melanoma With BRAF Mutations

The FDA approved the use of Braftovi and Mektovi in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by the THxID BRAF Kit (bioMérieux), which was also approved.
EHS
Back to top button